Evaluation of Rupture of Galenic Practices at Home in a Population Aged 65 or Older
NCT ID: NCT03681899
Last Updated: 2020-07-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
289 participants
OBSERVATIONAL
2018-09-18
2019-12-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The oral route is the preferred route of administration. The effectiveness and the safety of the drugs depend in particular on the modes of administration (frequency of the intake, respect of the doses and the galenic ...).
However, these modalities are very little known concerning the treatments intake at home in the elderly population.
In a health facility welcoming geriatric patients, the rupture of galenic is frequent and favored by swallowing disorders, dependence, the increase in age, the presence of cognitive disorders or psycho-behavioral disorders.
The consequences of the rupture of galenic are numerous, concern the patients but also the caregivers who administer the treatments.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cohort as Part of Undergraduate Medical Studies at the University of Sherbrooke
NCT03928509
Relationship Between Frailty and Gut Microbiota in Older Adults: An Educational Program for Healthy Aging
NCT07251322
Transcultural and Psychometric Validation of the Lubben Social Network Scale in Older Adults Living in the French West Indies
NCT06909591
Assessment of Routine Oral Screening Programs for New Prisoners
NCT03736070
Access to Healthcare and the Right to Health of People Living in Disadvantaged Neighborhoods Around Cayenne in French Guiana
NCT03359707
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
\- Estimate the rupture of galenic prevalence of at least one molecule in a population of subjects aged 65 years or over living at home and taking at least one oral drug for 2 weeks or more.
Secondary objectives:
* Identify the drug classes most frequently involved in the rupture of galenic in a population of subjects aged 65 years of age or over at home;
* Identify the actors of the drug administration in a population of subjects aged 65 years of or over at home;
* To determine the medical and sociodemographic factors associated with the rupture of galenic in a population of subjects aged 65 years or over at home;
* To determine the modalities of rupture of galenic in a population of subjects aged 65 or over at home.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Subjects aged of 65 years or older
Subjects aged of 65 years or older, taking at least one oral medication for two weeks or more.
Questionnaires
* Socio-demographic data (age, sex, place of residence, and family status, last occupation, existence or not of a primary caregiver (family and / or professional));
* Medical and surgical history (Charlson Comorbidity Scale);
* Assessment of oral/dental condition
* Record of drug treatments (number of oral medications per day, therapeutic class, number of daily intakes);
* Oral treatments intake modalities (galenic breakdown of one or more drugs, usual or occasional, modalities of rupture, person responsible for the drugs, mixing with food / drink);
* Autonomy evaluation (Lawton and Katz scales);
* Mobility assessment (anamnestic evaluation);
* Evaluation of Thyme (GDS 4 items);
* Psycho-behavioral disorders,
* Assessment of swallowing (presence of a diagnosis of dysphagia or suspicion based on anamnestic data).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Questionnaires
* Socio-demographic data (age, sex, place of residence, and family status, last occupation, existence or not of a primary caregiver (family and / or professional));
* Medical and surgical history (Charlson Comorbidity Scale);
* Assessment of oral/dental condition
* Record of drug treatments (number of oral medications per day, therapeutic class, number of daily intakes);
* Oral treatments intake modalities (galenic breakdown of one or more drugs, usual or occasional, modalities of rupture, person responsible for the drugs, mixing with food / drink);
* Autonomy evaluation (Lawton and Katz scales);
* Mobility assessment (anamnestic evaluation);
* Evaluation of Thyme (GDS 4 items);
* Psycho-behavioral disorders,
* Assessment of swallowing (presence of a diagnosis of dysphagia or suspicion based on anamnestic data).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient taking at least one oral medication for two weeks or more;
* Patient affiliated to a social security scheme;
* Patient who has agreed to reply to the questionnaire or, in case of inability to agree, agreement obtained from the caregiver or guardian/curator.
Exclusion Criteria
* Patient having changed residence for two weeks or less;
* Patient residing in a residential care facility for dependent elderly people.
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Center of Martinique
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Martinique
Fort-de-France, Martinique, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18_RIPH3-07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.